HSBC Holdings
MCRB icon

HSBC Holdings’s Seres Therapeutics MCRB Stock Holding History

HSBC Holdings’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-934
Closed -$14K – 3084
2024
Q2 		$14K Buy
934
+372
+66% +$6.21K ﹤0.01% 2887
2024
Q1 		$8.7K Buy
+562
New +$12.1K ﹤0.01% 3018

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

HSBC Holdings's MCRB Position: Q3 2024 in Review

HSBC Holdings sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 934 shares — an estimated $14K sold.

HSBC Holdings first reported a position in MCRB in Q1 2024 and held it in 2 quarters. The position peaked at $14K in Q2 2024. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

  • HSBC Holdings reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
  • HSBC Holdings sold 934 Seres Therapeutics shares in Q3 2024, an estimated $14K.
  • HSBC Holdings first reported a position in Seres Therapeutics in Q1 2024 and held it in 2 quarters.
  • HSBC Holdings's Seres Therapeutics position peaked at $14K in Q2 2024.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on HSBC Holdings's 13F filing for Q3 2024, filed 14 Nov 2024.